Intended for healthcare professionals

News

FDA proposes higher fees for drug approvals to cover postmarketing surveillance

BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39104.352616.DB (Published 25 January 2007) Cite this as: BMJ 2007;334:177